Join FierceBiotech at DIA

Just a quick reminder for everyone who's planning to attend DIA in Boston: I'll be on hand for FiercePharma's Cocktails on the Harbor networking event on Tuesday evening, June 24. Space is limited to RSVP now if you'd like to drop by for cocktails and to meet Tracy Staton, the editor of FiercePharma. We'll also be at DIA that week, so if you'd like to request a meeting, make sure to drop me a line. - John Carroll

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.